Search

Your search keyword '"Calvo, Mariona"' showing total 43 results

Search Constraints

Start Over You searched for: Author "Calvo, Mariona" Remove constraint Author: "Calvo, Mariona"
43 results on '"Calvo, Mariona"'

Search Results

3. Mevrometostat (PF-06821497), an enhancer of zeste homolog 2 (EZH2) inhibitor, in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC): A randomized dose-expansion study.

4. Assessing the impact of COVID-19 on liver cancer management (CERO-19)

5. External validity of docetaxel triplet trials in advanced gastric cancer: are there patients who still benefit?

9. Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study

10. Interim analysis of the ACTION trial: Cabozantinib for hepatocellular carcinoma patients who discontinued first line treatment other than sorafenib or due to sorafenib intolerance

11. Dissecting the role of the NADPH Oxidase NOX4 in TGF-beta signaling in hepatocellular carcinoma

12. A multi-center, open-label, randomized dose expansion study of PF-06821497, a potent and selective inhibitor of enhancer of zeste homolog 2 (EZH2), in patients with metastatic castration-resistant prostate cancer (mCRPC).

14. Myasthenia Gravis Induced by Immune Checkpoint Inhibitors: An Emerging Neurotoxicity in Neuro-Oncology Practice: Case Series

16. Survival and adverse events of elderly patients treated with sorafenib for hepatocellular carcinoma

17. Efficacy and safety of maintenance therapy with pamiparib versus placebo for advanced gastric cancer responding to first‐line platinum‐based chemotherapy: Phase 2 study results.

19. Myasthenia Gravis Induced by Immune Checkpoint Inhibitors: An Emerging Neurotoxicity in Neuro-Oncology Practice: Case Series.

20. En comunitat, utilitza la creativitat! Compartim els projectes de treball comunitari: fira de projectes

23. PARALLEL 303: Phase 2 randomized study of pamiparib vs placebo as maintenance therapy in patients (pts) with inoperable locally advanced or metastatic gastric cancer that responded to platinum-based first-line (1L) chemotherapy.

24. MONEO: A phase II study of avelumab (Av) plus FLOT in the peri-operative treatment for patients (pts) with resectable gastric or gastroesophageal junction cancer (GC).

25. THU-124 - Interim analysis of the ACTION trial: Cabozantinib for hepatocellular carcinoma patients who discontinued first line treatment other than sorafenib or due to sorafenib intolerance

26. External validity of docetaxel triplet trials in advanced gastric cancer: are there patients who still benefit?

27. Clinical significance of peritoneal molecular markers in patients with locally advanced gastric cancer (LAGC) without macroscopic peritoneal implants treated with perioperative chemotherapy (ChT).

28. PRÓTESIS DE APOSICIÓN LUMINAL EN EL DRENAJE BILIAR DE PATOLOGÍA BILIOPANCREÁTICA MALIGNA IRRESECABLE: EXPERIENCIA EN CENTRO TERCIARIO

30. Clinical relevance of histologic subtypes in locally advanced esophageal carcinoma treated with pre-operative chemoradiotherapy: Experience of a monographic oncologic centre

31. Radical chemoradiotherapy for patients with locally advanced esophageal cancer. Long-term follow up of an ambispective study

33. Neoadjuvant treatment in borderline resectable pancreatic adenocarcinoma (pa): a single center serie.

39. Impact of multidisciplinary cancer care on the postoperative mortality and survival of patients with esophageal and esophagogastric junction cancer.

41. P-0051 Prognostic Factors Correlated to Poor Outcome Among Patients with Potentially Curable Gastric Cancer Treated with Perioperative Chemotherapy

Catalog

Books, media, physical & digital resources